Pegaptanib is an anti-vascular endothelial growth factor (VEGF) therapy used to treat neovascular age-related macular degeneration (AMD). A randomized, double-blind, multicenter clinical trial evaluated pegaptanib at three doses (0.3 mg, 1.0 mg, and 3.0 mg) and sham injections in 1186 patients with AMD. The primary endpoint was the proportion of patients who maintained or improved visual acuity (measured in letters) at 54 weeks. Results showed that all three doses of pegaptanib significantly reduced the risk of visual acuity loss compared to sham injections. At week 54, 70% of patients receiving 0.3 mg of pegaptanib maintained or improved visual acuity, compared to 55% in the sham group. The risk of severe visual acuity loss (30 letters or more) was reduced from 22% to 10% with 0.3 mg. Pegaptanib also reduced the risk of severe vision loss in all dose groups compared to sham injections. Visual acuity improved as early as week 6, with continued improvement up to week 54. The drug was effective across all angiographic subtypes of AMD, lesion sizes, and baseline visual acuity levels. Adverse events were generally mild to moderate, with endophthalmitis, traumatic lens injury, and retinal detachment being the most serious. Pegaptanib showed long-term safety, though its long-term efficacy is not fully known. The study supports the use of anti-VEGF therapy for AMD, highlighting its effectiveness and safety profile. The findings suggest that pegaptanib is a viable treatment option for neovascular AMD, with potential benefits across a broad patient population.Pegaptanib is an anti-vascular endothelial growth factor (VEGF) therapy used to treat neovascular age-related macular degeneration (AMD). A randomized, double-blind, multicenter clinical trial evaluated pegaptanib at three doses (0.3 mg, 1.0 mg, and 3.0 mg) and sham injections in 1186 patients with AMD. The primary endpoint was the proportion of patients who maintained or improved visual acuity (measured in letters) at 54 weeks. Results showed that all three doses of pegaptanib significantly reduced the risk of visual acuity loss compared to sham injections. At week 54, 70% of patients receiving 0.3 mg of pegaptanib maintained or improved visual acuity, compared to 55% in the sham group. The risk of severe visual acuity loss (30 letters or more) was reduced from 22% to 10% with 0.3 mg. Pegaptanib also reduced the risk of severe vision loss in all dose groups compared to sham injections. Visual acuity improved as early as week 6, with continued improvement up to week 54. The drug was effective across all angiographic subtypes of AMD, lesion sizes, and baseline visual acuity levels. Adverse events were generally mild to moderate, with endophthalmitis, traumatic lens injury, and retinal detachment being the most serious. Pegaptanib showed long-term safety, though its long-term efficacy is not fully known. The study supports the use of anti-VEGF therapy for AMD, highlighting its effectiveness and safety profile. The findings suggest that pegaptanib is a viable treatment option for neovascular AMD, with potential benefits across a broad patient population.